Eupraxia Pharmaceuticals Bolsters Board with Drug Development Veterans — Eupraxia Pharmaceuticals Inc.

Event summary

Eupraxia Pharmaceuticals appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors on July 7, 2026.
Robert Bazemore brings over 30 years of experience in drug development and commercialization, including roles at Epizyme, Synageva BioPharma, Johnson & Johnson, and Merck & Co.
Amy Pott has extensive commercial strategy experience from Astellas Pharma, Swedish Orphan Biovitrum, Shire, and Baxalta.
Dr. Helen Thackray offers 25 years of leadership in R&D and clinical development, previously serving as Chief Research and Development Officer at BioCryst Pharmaceuticals.

The big picture

Eupraxia Pharmaceuticals is fortifying its governance with seasoned industry leaders as it navigates critical milestones for its lead candidates, EP-104GI and EP-104IAR. The appointments reflect a strategic push to enhance late-stage development capabilities and commercial readiness, aligning with broader trends in biotech where specialized board expertise is increasingly seen as a competitive advantage. With its proprietary Diffusphere™ technology targeting high-unmet medical needs, Eupraxia aims to carve out a niche in gastroenterology and beyond.

What we're watching

Strategic Alignment: How the new board members' expertise in late-stage drug development and commercialization will influence Eupraxia's pipeline expansion.
Execution Risk: Whether the company can leverage the new board's experience to accelerate the Phase 1b/2 trial of EP-104GI for EoE.
Market Positioning: The pace at which Eupraxia can differentiate its Diffusphere™ technology in competitive therapeutic areas like oncology and infectious diseases.